
|Articles|May 31, 2022
Daily Medication Pearl: Voriconazole (Vfend)
Author(s)Saro Arakelians, PharmD
Voriconazole (Vfend) is an azole antifungal indicated for the treatment of invasive aspergillosis and Candidemia in non-neutropenics and other deep tissue Candida infections.
Advertisement
Medication Pearl of the Day: Voriconazole (Vfend)
Indication: Voriconazole (Vfend) is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with invasive aspergillosis and Candidemia in non-neutropenics and other deep tissue Candida infections.
Insight:
- Dosing: May start from 4 mg/kg/day and extend to 9 mg/kg/day based on the patient.
- Dosage forms: Tablets 50 mg, 200 mg.
- Adverse events: The most common adverse reactions (incidence ≥2%) were visual disturbances, fever, nausea, rash, vomiting, chills, headache, liver function test abnormal, tachycardia, and hallucinations.
- Mechanism of action: Voriconazole is an antifungal drug.
Source:
https://labeling.pfizer.com/showlabeling.aspx?id=618
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Enfortumab Vedotin Plus Pembrolizumab Shows Promise as a Platinum-Free Option in Earlier Bladder Cancer
2
FDA Approves Rucaparib for the Treatment of Adults With mCRPC
3
Updates in Treatment of Unresectable Hepatocellular Carcinoma
4
Notable Updates in Medication Therapy Management in 2025
5









































































































































































































